Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma

Hormone-dependent endometrial adenocarcinomas are responsive to Tamoxifen at a daily oral dosage ranging from 40 to 60 mg. This responsiveness is manifested by marked histochemical and histological transformations of the adenocarcinoma, leading finally to atrophy and disappearance of the tumor. Seco...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Gynecologic oncology 1981-04, Vol.11 (2), p.140-161
Hauptverfasser:	Bonte, J., Ide, P., Billiet, G., Wynants, P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - blood Adenocarcinoma - drug therapy Adenocarcinoma - pathology Cells, Cultured Estrone - blood Female Follicle Stimulating Hormone - blood Humans Luteinizing Hormone - blood Neoplasm Recurrence, Local - drug therapy Receptors, Progesterone - metabolism Tamoxifen - therapeutic use Uterine Neoplasms - blood Uterine Neoplasms - drug therapy Uterine Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!